The role of agomelatine in appetite regulation and body weight in rats
Experimental Physiology · 2026
DOI: 10.1113/ep092783 ↗At a glance
Journal article in Experimental Physiology, 2026. Written by Engin Korkmaz and 3 co-authors. Institution: Faculty of Medicine, Department of Physiology, İnönü University, Malatya, Türkiye. Major MEDLINE topics: Acetamides, Appetite Regulation, Body Weight, Appetite. Cited 2 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY 4.0). Funded by: The Scientific and Technological Research Council of Türkiye (TÜBİTAK).
Abstract (original language)
The hypothalamic nuclei play a central role in the synthesis of anorexigenic and orexigenic neuropeptides, which are regulated by peripheral hormones, like leptin and ghrelin. Melatonergic receptors (MT 1 /MT 2 ) are prominently expressed in the arcuate nucleus of the hypothalamus – an essential hub for appetite control – and in peripheral metabolic tissues where leptin and ghrelin are secreted. Agomelatine, an antidepressant drug and potent MT 1 /MT 2 agonist, offers potential for modulating appetite. This study aimed to investigate the impact of agomelatine on appetite regulation. Forty male Sprague–Dawley rats were randomly allocated into four groups, control (no treatment), vehicle control, agomelatine 20 mg/kg (Ago‐20), and agomelatine 40 mg/kg (Ago‐40), and administered oral gavage for 14 days. Body weight and food intake were recorded daily. At the end of the experiment, rats were euthanized and blood and hypothalamic tissue samples were obtained. Agomelatine significantly reduced body weight (Ago‐40: 275.2 ± 7.2 g vs. control: 339.7 ± 8.3 g, P < 0.05) and food intake (Ago‐40: 20.21 ± 1.32 g vs. control: 32.09 ± 1.58 g, P < 0.05) by day 14, without affecting water intake. Plasma ghrelin levels decreased (Ago‐40: 22.54 ± 3.95 ng/dL vs. control: 46.67 ± 4.84 ng/dL, P < 0.05), while leptin increased (Ago‐40: 552.30 ± 41.67 pg/mL vs. control: 271.10 ± 32.12 pg/mL P < 0.05). Hypothalamic orexigenic neuropeptides neuropeptide Y (NPY) and agouti‐related peptide (AgRP) were suppressed (NPY, Ago40: 0.61 ± 0.02 vs. Control: 1.36 ± 0.1321; AgRP, Ago40: 0.52 ± 0.03 vs. Control: 1.49 ± 0.27, P < 0.05), while anorexigenic cocaine‐ and amphetamine‐regulated transcript (CART) and proopiomelanocortin (POMC) were elevated (CART: Ago40: 1.19 ± 0.08 vs. Control: 0.92 ± 0.06; POMC: Ago40: 1.49 ± 0.17 vs. Control: 0.67 ± 0.10, P < 0.05). These findings suggest agomelatine promotes weight loss by modulating appetite‐related hormones and hypothalamic neuropeptides, highlighting its potential as a therapeutic for obesity and metabolic disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Medicine, Department of Physiology, İnönü University, Malatya, Türkiye.
- Faculty of Science, Department of Molecular Biology and Genetics, Bartın University, Bartın, Türkiye.
- Vocational School of Health Services, Department of Health Care Services, İnönü University, Malatya, Türkiye.
ORCID profiles: Suat Tekin
Funding
- The Scientific and Technological Research Council of Türkiye (TÜBİTAK)
Cite
APA
Korkmaz, E., Erden, Y., Tekin, Ç., & Tekin, S. (2026). The role of agomelatine in appetite regulation and body weight in rats. Experimental Physiology. https://doi.org/10.1113/ep092783
Vancouver
Korkmaz E, Erden Y, Tekin Ç, Tekin S. The role of agomelatine in appetite regulation and body weight in rats. Experimental Physiology. 2026. doi:10.1113/ep092783
BibTeX
@article{Korkmaz2026,
author = {Korkmaz, Engin and Erden, Yavuz and Tekin, Çiğdem and Tekin, Suat},
title = {The role of agomelatine in appetite regulation and body weight in rats},
journal = {Experimental Physiology},
year = {2026},
doi = {10.1113/ep092783}
}
EUVIMED